An Umbrella Trial Based on Molecular Pathway for Patients With Metastatic TNBC.

Conditions

• TNBC - Triple-Negative Breast Cancer

Interventions

• DRUG: A1: Pyrotinib with nab-paclitaxel
• DRUG: A2: nab-paclitaxel
• DRUG: B1: everolimus with nab-paclitaxel
• DRUG: B2: nab-paclitaxel
• DRUG: C1: PD-1 with nab-paclitaxel and famitinib
• DRUG: C2: nab-paclitaxel
• DRUG: D1: VEGFR and nab-paclitaxel, with maintenance of VEGFR and capecitabine
• DRUG: D2: nab-paclitaxel, with maintenance of capecitabine
• DRUG: E1: everolimus with nab-paclitaxel
• DRUG: E2: nab-paclitaxel

Sponsor

Fudan University